MindMed Advances MM120 for GAD

By Tamara Parker • Thursday, June 20 15:27 • Permanent Link

MindMed Inc. has announced the completion of an end-of-phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for its product candidate MM120, a treatment for generalized anxiety disorder (GAD). The meeting has resulted in alignment on the requirements for the phase 3 clinical development of MM120 for the treatment of GAD, and the initiation of the phase 3 program remains on schedule to begin in the second half of 2024.

Results from MindMed's completed phase 2b clinical trial, Mmed008, were presented at the EOP2 meeting. In this trial, MM120 demonstrated a rapid, clinically meaningful, and statistically significant improvement on the Hamilton Anxiety Rating Scale (HAM-A) at week 4 and week 12. The MM120 100 µg cohort showed a 65% clinical response rate and 48% clinical remission rate sustained to week 12. The trial also found that MM120 was generally well-tolerated, with most adverse events rated as mild to moderate and transient.

GAD is a common condition affecting millions of people, with approximately 20 million adults in the U.S. currently suffering from the disorder. MindMed's Chief Executive Officer, Rob Barrow, expressed enthusiasm for the therapeutic potential that MM120 shows based on the data from the phase 2b trial. The company is committed to bringing MM120 to people living with GAD and is excited to move into the next phase of the development program.

MindMed is a clinical stage biopharmaceutical company focused on developing novel product candidates to treat brain health disorders. The company's mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. MindMed trades on NASDAQ under the symbol MNMD.

The announcement positions MindMed to progress MM120 into pivotal trials for the treatment of adults with GAD, marking a significant milestone for the company and potentially offering hope for individuals impacted by the disorder. As a result of these announcements, the company's shares have moved 0.0% on the market, and are now trading at a price of $7.32. For the full picture, make sure to review Mind Medicine (MindMed)'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.